Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

(2009) S.-Y. Wang et al.   BLOOD

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

Structural Difference in the Complement Activation Site of Human IgG1 and IgG3

(2009) T. E. Michaelsen et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities

(2008) A. Natsume et al.   CANCER RESEARCH

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

(2008) M. Dechant et al.   CANCER RESEARCH

Molecular engineering and design of therapeutic antibodies

(2008) Leonard G Presta   CURRENT OPINION IN IMMUNOLOGY

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

(2008) Clive S. Zent et al.   LEUKEMIA RESEARCH

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies

(2008) Seung Y. Chu et al.   MOLECULAR IMMUNOLOGY

The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy

(2008) X. Zhou et al.   ONCOLOGIST